The November election is over, but the real campaign has just begun. For urologists, that means urgent action on efforts to reverse the payment cuts mandated by the sustainable growth rate formula and the fiscal cliff, to name two immediate priorities.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Clarke Drive
Cranbury, NJ 08512